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Abstract 
Background: Tuberous sclerosis complex (TSC) is a rare multisystem autosomal dominant disorder caused by 
pathogenic variants in either the TSC1 or TSC2 gene. Common manifestations of TSC have been grouped into major 
and minor clinical diagnostic criteria and assessed in clinical routine workup. However, case studies point towards the 
existence of rare disease manifestations and to the potential association of TSC with malignant tumors. In this study 
we sought to characterize rare manifestations and malignancies using a large cohort of patients.
Methods: TuberOus SClerosis registry to increAse disease awareness (TOSCA) is a multicenter, international disease 
registry collecting clinical manifestations and characteristics of patients with TSC, both retrospectively and prospec-
tively. We report rates and characteristics of rare manifestations and malignancies in patients with TSC who had 
enrolled in the TOSCA registry. We also examined these manifestations by age, sex, and genotype (TSC1 or TSC2).
Results: Overall, 2211 patients with TSC were enrolled in the study. Rare manifestations were reported in 382 (17.3%) 
study participants and malignancies in 65 (2.9%). Of these rare manifestations, the most frequent were bone sclerotic 
foci (39.5%), scoliosis (23%), thyroid adenoma (5.5%), adrenal angiomyolipoma (4.5%), hemihypertrophy and pancre-
atic neuroendocrine tumors (pNET; both 3.1%). These rare manifestations were more commonly observed in adults 
than children (66.2% vs. 22.7%), in females versus males (58.4% vs. 41.6%; except for scoliosis: 48.9% vs. 51.1%), and in 
those with TSC2 versus TSC1 (67.0% vs. 21.1%; except for thyroid adenoma: 42.9% vs. 57.1%). In the 65 individuals with 
reported malignancies, the most common were renal cell carcinoma (47.7%), followed by breast (10.8%) and thyroid 
cancer (9.2%). Although malignancies were more common in adult patients, 26.1% were reported in children and 
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Introduction
Tuberous sclerosis complex (TSC) is a rare autosomal 
dominant disorder caused by pathogenic variations in 
the TSC1 or TSC2 gene. This results in hyperactivation 
of the mammalian/mechanistic target of rapamycin path-
way, leading to hamartoma formation. The prevalence of 
TSC is estimated to be between 1/6800 and 1/15,000 and 
the incidence is estimated to be nearly 1:6000–10,000 live 
births [1–3]. It can affect all organ systems, leading to 
diverse clinical manifestations and has a broad variability, 
not only among individual patients but also within the 
affected families [1].
The 2012 International Tuberous Sclerosis Complex 
Consensus Conference provided recommendations to 
standardize the approach to manage this disorder. A 
system of major and minor criteria serves as a basis to 
establish the diagnosis clinically. Recommendations on 
surveillance and treatment mainly focus on these criteria 
[4]. However, the involvement of multiple organ systems 
at different stages of life presents a major challenge in 
the comprehensive clinical management of patients with 
TSC.
Over the last two decades, several clinical pathologies 
have been identified as associated with TSC, such as aor-
tic and intracranial aneurysm [5, 6], arachnoid cysts [7, 
8], lymphedema [9, 10], pancreatic endocrine tumor [11], 
pituitary adenoma [7], chordoma [12], and bone sclerotic 
foci [13]. Although these clinical pathologies are less fre-
quent and not included as clinical diagnostic criteria, 
some of them can be life-threatening, while others may 
be challenging to integrate into a comprehensive clini-
cal picture of the patients. Identification of these rare or 
less frequent manifestations and their clinical character-
istics may help in their early diagnosis and contribute to 
ultimately preventing morbidity and mortality in patients 
with TSC.
A second important controversy in TSC is the fact that 
it remains a debate whether patients with TSC have an 
increased risk for malignant tumors. Until now, mostly 
renal cell carcinoma [14] has been identified in this 
context.
To the best of our knowledge, no systematic evalua-
tion of these manifestations has been performed to date 
in a large patient cohort that might provide reliable 
results to aid clinicians in the management of TSC. Our 
aim is to present the rates and characteristics of vari-
ous rare manifestations and malignancies observed in 
patients with TSC enrolled in the TuberOus SClerosis 
registry to increAse disease awareness (TOSCA) study 
and report differences in these rare manifestations and 
malignancies by sex, age, and TSC mutation.
Materials and methods
Study design, participants and data collection
A detailed methodology of the study has been pub-
lished previously [15]. In brief, TOSCA is a multi-
center, international disease registry structured to 
collect patient and disease information retrospectively 
and prospectively. It consists of a ‘core’ section and six 
‘petals’ or ‘research projects’. In the core section of the 
study, information on the patient’s background, includ-
ing demographics, familial and prenatal history, vital 
signs, and disease features, were collected at baseline 
and updated annually, wherever possible. Additional 
detailed information was collected in the six research 
projects that focused on subependymal giant cell astro-
cytoma, renal angiomyolipoma and lymphangiomy-
omatosis, genetics, TSC-associated neuropsychiatric 
disorders (TAND), epilepsy, and quality of life. Here, 
we present data on the rare manifestations, comor-
bidities and malignancies from the core section of the 
TOSCA registry.
Patients of any age with a documented visit for TSC 
in the preceding 12  months or newly diagnosed with 
TSC were enrolled into the TOSCA registry after 
obtaining written informed consent. Investigators col-
lected data on rare manifestations by either selecting 
predefined items known to be associated with TSC or 
entering other items in a free text field.
For malignancies, data were collected for those 
patients who had either one or more of a number of 
predefined malignancies (renal, ovarian, testicular, and 
gastrointestinal malignancies). In addition, investiga-
tors could enter any other malignancy in a free text 
field.
63.1% in individuals < 40 years. TSC1 mutations were over-represented in individuals with malignancies compared to 
the overall TOSCA cohort (32.1% vs. 18.5%).
Conclusion: Rare manifestations  were observed in a significant proportion of individuals with TSC. We recommend 
further examination of rare manifestations in TSC. Collectively, malignancies were infrequent findings in our cohort. 
However, compared to the general population, malignant tumors occurred earlier in age and some tumor types were 
more common.
Keywords: Rare manifestation, Malignancy, TOSCA, TSC, Tuberous sclerosis complex
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Assessments
Demographic and baseline characteristics between 
the patients with and without rare manifestations, and 
between patients with and without malignancies, were 
compared. For the purpose of this study, we defined 
rare manifestations as all manifestations declared as 
rare and disease-related by the investigators that did 
not fit under major or minor TSC clinical criteria as 
outlined in the 2012 Tuberous Sclerosis Consensus 
Conference recommendations and that were not a clear 
sequelae of major or minor manifestations (such as 
epilepsy).
We have prospectively categorized the rare manifes-
tations by sex and mutation type, and by several syn-
dromal complexes, such as tumors, malformations, 
vascular malformations, cystic lesions, endocrine dis-
orders, and others (Table 2). Rare manifestations were 
also categorized into the following organ classes: vas-
culature, ear, nose and throat, endocrine system, eye, 
heart, gastrointestinal, liver, lymphatic tissue, nervous 
system, skeletal, urogenital, and others (Additional File 
1: Table S1).
Rare manifestations reported by investigators in the 
free text field of the case report form that did not have 
an unambiguous description, were clearly not rare 
manifestations, or were typical manifestations of TSC 
(major/minor diagnostic criteria or epilepsy) were 
excluded from the analysis (Additional File 1: Table S2).
Malignancies observed in the TOSCA cohort were 
reported by organ. Rare manifestations and malignan-
cies (either predefined or open field) were grouped 
based on organ system, and further by age, sex, and 
genotype. Available information on the age at first TSC 
diagnosis, mutation type and patient who received 
treatment for rare manifestation and malignancies are 
reported.
Statistical analysis
All patients, without any major protocol deviation, 
enrolled in the TOSCA clinical study were included for 
analysis. SAS® Version 9.2 or later was used to perform 
all statistical analyses. Continuous variables were sum-
marized with descriptive statistics (n, mean, standard 
deviation, range [minimum and maximum] and median). 
Frequency counts and the percentage of patients within 
each category were used for categorical data. Demo-
graphic and baseline characteristics between patients 
with and without rare manifestations and between 
patients with and without malignancies were compared 
using chi-square test for association and Z-test for 
means, as appropriate. A p value < 0.05 was considered 
statistically significant.
Results
Patient demographics and clinical characteristics
A total of 2211 patients with TSC were enrolled in the 
TOSCA registry. Of those, 382 (17.3%) individuals had 
rare manifestations and 65 (2.9%) had malignancies 
reported by investigators. Demographic characteristics in 
patients with and without rare manifestations and malig-
nancies are shown in Table 1.
In patients with rare manifestations, TSC was diag-
nosed later than in those without (median: 2  years vs. 
1  year; p < 0.0001). The female to male ratio was higher 
Table 1 Demographic characteristics in patients with and without rare manifestations and in patients with and without malignancies
NMI, no mutation identified; NS, not significant; SD, standard deviation; TSC, tuberous sclerosis complex
Characteristics Patients with rare 
manifestations, n 
(%)
Patients without rare 
manifestations, n (%)







Age at consent, years N = 382 N = 1829 N = 65 N = 2146
Mean (SD) 28.4 (16.71) 15.0 (14.15)  < 0.0001 32.7 (18.86) 16.9 (15.11)  < 0.0001
Median (range) 26.0 (0–71) 10.0 (0–71) 31 (0–68) 12 (0–71)
Age at first TSC diagnosis, years
Mean (SD) 12.4 (16.68) 5.8 (10.87)  < 0.0001 16.9 (18.94) 6.6 (11.95)  < 0.0001
Median (range) 2.0 (0–69) 1.0 (0–67) 10.5 (0–67) 1 (0–69)
Sex, n (%)
Male 159 (41.6) 900 (49.2) 0.007 22 (33.8) 1036 (48.3) 0.0214
Female 223 (58.4) 928 (50.8) 43 (66.2) 1109 (51.7)
Mutation, n (%)
TSC1 39 (21.1) 152 (18.4) NS 10 (32.3) 181 (18.5) 0.0366
TSC2 124 (67.0) 525 (63.6) 15 (48.4) 634 (64.7)
NMI 19 (10.3) 129 (15.6) 6 (19.4) 142 (14.5)
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in patients with rare manifestations than in those without 
(female vs. male; 58.4% vs. 41.6% compared to 50.8% vs. 
49.2%, respectively; p = 0.007). There was no difference in 
the mutation types (TSC1, TSC2 or no mutation identi-
fied [NMI]) in participants with rare manifestations com-
pared to individuals without (p = 0.687).
In patients with malignancies, TSC was diagnosed 
later compared to those without malignancies (median: 
10.5  years vs. 1  year; p < 0.0001). We found a higher 
female to male ratio in patients with malignancies com-
pared to individuals without malignancy (66.2%:33.8% vs. 
51.7%:48.3%; p = 0.021). Considering differences in muta-
tions, participants with malignancies had a significantly 
higher rate of TSC1 mutations than participants without 
malignancies (TSC1 vs. TSC2 vs. NMI; 32.3% vs. 48.4% vs. 
19.4% and 18.5% vs. 64.7% vs.14.5%, respectively; p = 0.037).
Rare manifestations
In this study, 88 different manifestations were identi-
fied that were designated by the investigators as rare 
TSC-associated manifestations (Table  2). The five most 
frequent rare manifestations were bone sclerotic foci 
(39.5%), scoliosis (23%), thyroid adenoma (5.5%), adre-
nal angiomyolipoma (4.5%), hemihypertrophy and pNET 
(3.1% each) (Table 3).
Of the 382 patients with rare manifestations, tumors 
and cystic lesions were reported in 268 (tumors in 248 
patients and cystic lesions in 20 patients), with female 
patients being more commonly affected than males 
(60.5% vs. 39.5%). Malformations were reported in 124 
patients, equally affecting both sexes (male vs. female; 
51.3% vs. 48.7%) and a majority of patients having TSC2 
mutation (85.2%). Malformations were observed at an 
earlier age (median age, 11 years), while tumors (median 
age, 28  years), cystic lesions (median age, 27  years), 
and endocrine disorders (median age, 31.5  years) were 
observed at a later age (Table 4).
As reported above, rare manifestations were predomi-
nant in female compared to male patients, except for sco-
liosis which was a little more frequent in male patients 
(51.1% vs. 48.9%; p = 0.733). Similar distribution pat-
terns of TSC gene mutation were noted in patients with 
or without rare manifestation, i.e. rate of TSC2 mutation 
being more than TSC1, with the exception of patients 
with thyroid adenoma who had a higher rate of TSC1 
mutations than TSC2 (57.1% vs. 42.9%; p = 0.512). Upon 
stratification by age group, rare manifestations were 
more common in adult patients (> 18 years) (Table 5).
Malignancies
Malignancies were reported in 65 patients. Most fre-
quent malignancies observed were renal cell carcinoma 
(47.7%), breast cancer (10.8%), and thyroid cancer (9.2%).
Altogether, the percentage of female patients was 
significantly higher in the group of participants with 
malignancies (66.2%) compared to participants without 
malignancies (51.7%; p = 0.021) (Table  1). The predomi-
nance of females was consistent in patients with renal 
cell carcinoma (64.5%), but didn’t reach a  statistical sig-
nificance. In addition, the TSC1:TSC2 ratio was signifi-
cantly higher in patients with malignancies (TSC1 vs. 
TSC2 vs. NMI was 32.3% vs. 48.2% vs. 19.4%) compared 
to individuals without malignancies (18.5%:64.7%:14.5%; 
p = 0.037). Accordingly, the TSC1:TSC2 ratio was mark-
edly higher in patients with renal malignancy (36.4% 
vs. 53.3%) than in patients without malignancy (18.5% 
vs. 64.5%). Thyroid carcinoma (n = 6) was exclusively 
reported in six female patients, of which half had TSC1 
mutations (Table 6).
Patients with malignancy appeared to be older (median 
32.7  years) than those without (median 12  years; 
p < 0.0001). Overall, malignancies were more common 
in adult patients (≥ 18  years) compared with pediatric 
patients (< 18  years) (Table  7). However, it is important 
to state that nearly one-third of renal cell carcinoma 
cases, half of thyroid carcinomas, half of bone and soft 
tissue malignancies, one-fourth of ovarian malignancies, 
and all of the pancreatic malignancies occurred in chil-
dren (≤ 14  years). Overall, 26% (n = 17) of malignancies 
were detected in patients < 18 years and 63.1% (n = 41) in 
those < 40 years (Table 7). Three patients (all female) had 
two different malignancies: one patient had ovarian and 
thyroid malignancies, the second patient had colon and 
breast malignancies, and the third patient had renal and 




The consensus clinical TSC diagnostic criteria include 
commonly presented TSC manifestations and the sur-
veillance recommendations mainly focus on these mani-
festations [4]. However, there are numerous additional 
manifestations of TSC that are reported. They may occur 
quite frequently (for example, bone sclerotic foci), but 
may be systematically missed as they are not usually of 
clinical relevance. This large cohort study provides a clear 
estimate of the frequency of rare manifestations. Bone 
sclerotic foci might be mainly detected as a by-product of 
thoracic computed tomography scans, which are recom-
mended for adult women affected by TSC only in order 
to screen for lymphangioleiomyomatosis (LAM) [16]. 
This might explain the clear female predominance of this 
manifestation in our study. Although of minor clinical 
relevance, it is important to know about this rather fre-
quent ‘rare manifestation’ as bone sclerotic foci could be 
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misinterpreted as bone metastasis or bone secondaries, 
which might result in unnecessary and potentially inva-
sive assessments [4, 17] in spite being a common benign 
manifestation of TSC. Expert advice should be sought in 
case of doubt in these patients.
In addition, bone sclerotic lesions are discussed to dif-
ferentiate TSC-associated LAM from sporadic LAM [16]. 
Given its frequency, one could argue for introducing 
bone sclerotic foci to the clinical diagnostic criteria.
The consensus guidelines further recommend exclud-
ing TSC-associated manifestations, such as  bone cysts, 
endocrinopathies, vascular aneurysms, and gastrointesti-
nal polyps,  from routine evaluation unless coupled with 
clinical symptoms or history due to the insufficient evi-
dence of benefit [1].
TSC is a multisystem disorder based on defects in 
tumor suppressor genes. We therefore hypothesized that 
there might be additional rare manifestations and asked 
investigators to document clinical signs considered as 
possible TSC-associated rare manifestations.
In total, 88 different rare manifestations were recorded 
in 17.3% of patients in this study. This shows the com-
plexity of the disease and highlights the limitations of 
systematic evaluation and treatment of rare manifesta-
tions. Most rare manifestations were more common in 
female patients and those with TSC2 mutations, which 
is in line with findings from previous literature on rare 
manifestations such as lymphedema and angiomyoli-
poma [10, 18]. Tumors and cystic lesions in a broad vari-
ety of organs seem to occur (or at least are detected) at 
higher ages. However, clinical significance seems limited 
in most cases, as treatment was reported for only 16% 
of tumors and 5% of cysts. It is worth noting that treat-
ment rates differed markedly depending on organ system. 
Details are given in Additional File 1: Table S1.
A relevant number of rare manifestations were malfor-
mations (occurring at younger ages), of which scoliosis 
and hemihypertrophy were the most frequent. Diagno-
sis of musculoskeletal malformations can be performed 
easily via careful physical examination in most cases, 
which might contribute to detection at an earlier age. 
Whereas hemihypertrophy was clearly more frequent 
in our cohort compared to the overall population (1 in 
86,000 live births), the rate of scoliosis did not differ from 
reports of adolescent idiopathic scoliosis (3.8% vs. 3.3%) 
[19, 20]. This might raise the question of whether scolio-
sis is a (rare) manifestation of TSC or a coincidental find-
ing. Although causality cannot be proven by a registry 
study, it is worth mentioning that 22.7% of the scoliosis 
patients in our study required treatment (compared to 
0.3% with adolescent idiopathic sclerosis). This possibly 
points toward a higher degree of severity or an underes-
timation of mild cases [21]. As previously reported, vas-
cular malformations, including arterial aneurysms, can 
occur in patients but seem to be quite rare (n = 5 corre-
sponding to 0.2% of the participants) (Table 5). Therefore, 
our data supports the 2012 consensus recommendations 
on not to perform the routine evaluation given the sparse 
numbers. If routine imaging of the brain is performed, it 
seems justifiable to screen for blood vessel abnormalities 
as 75% of arterial aneurysms in our cohort were reported 
to occur in the extra- or intracranial brain-supporting 
vessels [4].
Table 4 Malformations, tumors, and other manifestations in patients with rare manifestations
*Includes patients with laryngomalacia, lymphedema and myositis ossificans


























28 (0–69) 27 (10–62) 11 (0–50) 24.5 (0–50) 9.5 (0–48) 31.5 (2–48)
Sex Male Female Male Female Male Female Male Female Male Female Male Female




TSC1 TSC2 TSC1 TSC2 TSC1 TSC2 TSC1 TSC2 TSC1 TSC2 TSC1 TSC2
27 (26.2) 76 (73.8) 3 (23.1) 10 (76.9) 8 (14.8) 46 (85.2) 1 (100) 0 1 (14.3) 6 (85.7) 0 3 (100)
Treat-
ment
40 (16.2) 1 (5.0) 26 (21.8) 3 (60.0) 5 (55.6) 4 (66.7)
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Malignancies
The TSC consensus guidelines do not specifically com-
ment on the surveillance of malignancies in patients 
with TSC [4]. It is still a matter of debate whether TSC 
patients have an increased risk of malignant tumors [14].
This is the first study to report malignancies in a 
large and multinational cohort of patients with TSC. 
No deaths were reported due to malignancy during the 
study. Although, the overall rate of malignancies in our 
study was higher than reported by Jozwiak et  al. [22] 
(2.9% vs. 1.1%), but taken as a whole, still low. Notably, 
TOSCA participants, including the cohort of patients 
with malignancy, were markedly younger (median age 
31 years) compared to the overall population. This might 
explain why several other tumor types were found to be 
predominant in this cohort compared to the overall pop-
ulation. The most frequent cancer entities in the overall 
population, such as lung, colorectal, and prostate cancer 
(in men), occur at older median ages. Only breast cancer, 
which is the most frequent cancer in the overall female 
population, was also a frequent cancer type seen in our 
cohort [23].
The most frequent type of malignancy in our cohort 
was renal cell carcinoma, affecting 1.4% (31 patients) of 
participants, majorly observed in pediatric and young 
adults (10 patients, ≤ 18  years). The rate of renal cell 
carcinoma considerably exceeds the prevalence in the 
overall population. Similar findings have been reported 
previously; Yang et  al. (2014) referred to an overall 
incidence of 2% to 4% for renal malignancies [23] and 
Peron et al. (2016) reported an overall renal cell carci-
noma rate of 2.1% [14]. TSC-associated renal malignan-
cies have been reported to be more frequently observed 
in females, which is in contrast with the overall popu-
lation where the rate of renal malignancy is higher in 
males (6.6 vs. 3.9 per 100,000) (2). We, too, observed 
a higher rate of renal malignancy in female patients 
(64.5%).
All six thyroid cancer cases in our study were 
observed in females only, which seems to be more fre-
quent than in overall population (compare Table  6). 
Another frequent tumor type observed in our cohort 
was breast cancer (females only), which is, however, the 
most frequent cancer type in the overall population. 
Interestingly, patients with PTEN hamartoma tumor 
syndromes are at higher risk for both aforementioned 
tumor entities (cumulative cancer risk at age 70: 77% 
for female breast cancer and 38% for thyroid cancer) 
[25]. Analogical to the TSC1 and TSC2 complex, PTEN 
is another negative regulator of the mTOR pathway.
It is important to be aware of malignancies in patients 
with TSC, even at young ages. The occurrence of renal 
cell carcinoma in children has been reported previously 
[18] and was evident in our cohort as well. Malignancies 
were not limited to adult individuals with TSC; approxi-
mately 25% of malignancies in our study were observed 
in individuals younger than 18 years and 63.1% in partici-
pants younger than 40 years, similar to Peron et al. [14]. 
Given the overrepresentation of young patients in our 
study (63.3% were younger than 19 years and 89.5% were 
Table 6 Rate of malignancies in different organs in all patients, by sex and genotype
*Melanoma of skin. $5-year prevalence of malignancies have been presented for qualitative comparison between the general population and our cohort. NE, non-
estimable; NS, not significant
Organs 5-year prevalence of 
malignancies in general 
population (per 100, 000)$, 25
All, n (%)
N = 65
Sex, n (%) Mutation, n (%)









Kidney 13.4 16.5 10.3 31 (47.7) 11 (47.8) 20 (47.6) NS 4 (36.4) 8 (53.3) 0.3176
Breast 181.8 – 181.8 7 (10.8) 0 7 (16.7) 0.0159 1 (9.1) 1 (6.7) 0.3961
Thyroid 26.2 11.2 41.4 6 (9.2) 0 6 (14.3) 0.0159 3 (27.3) 1 (6.7) 0.0104
Testis 7.4 7.4 – 5 (7.7) 5 (21.7) 0 0.0265 1 (9.1) 0 0.2230
Ovary 20.2 – 20.2 4 (6.2) NA 4 (9.5) NS 1 (9.1) 3 (20.0) 1.000
Bone, soft tissue – – – 2 (3.1) 2 (8.7) 0 NS 0 1 (6.7) 1.000
Colon 62.8 67.4 58.0 2 (3.1) 0 2 (4.8) NS 0 0 NE
Lung 27.9 34.1 21.6 2 (3.1) 0 2 (4.8) NS 1 (9.1) 0 0.2230
Pancreas 3.7 3.9 3.5 2 (3.1) 2 (8.7) 0 NS 0 1 (6.7) 1.000
Brain (cerebral) 10.1 10.3 9.9 1 (1.5) 1 (4.3) 0 NS 0 0 NE
Eye – – – 1 (1.5) 0 1 (2.4) NS 0 0 NE
Liver 8.8 12.2 5.4 1 (1.5) 1 (4.3) 0 NS 0 0 NE
Skin* 12.7 13.1 12.2 1 (1.5) 1 (4.3) 0 0.4835 0 0 NE
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younger than 41  years at inclusion), overall malignancy 
rates in TSC patients might be underestimated as most 
malignant tumors occur at higher ages.
In this study, the genotype–phenotype correlations 
were difficult to establish due to the low number of 
patients with malignancies. We report 32.3% of patients 
with malignancy harboring TSC1 mutations compared 
to only 18.5% of patients who did not have malignancy. 
A previous study similarly reported a predominance 
of TSC1 mutations in patients with malignancies [14]. 
TSC1 contributes to both tumor-suppressive and pro-
metastatic action of the TGF-β-Smad pathway and works 
independently of TSC2, which is essential for cellular 
growth arrest and epithelial to mesenchymal transition 
[26]. This could be one possible reason for TSC1 predom-
inance in patients with malignancies in our study. How-
ever, further research will be necessary to elucidate the 
molecular mechanisms.
The evaluation of rare manifestations in this study had 
several limitations. First, a sign or symptom was recorded 
as a rare manifestation of TSC per the investigator’s 
definition. Second, no systematic screening for specific 
manifestations was performed in the study, except inves-
tigations performed in routine clinical practice. The first 
bears the risk of falsely collating a coincident symptom 
(especially if recorded infrequently) as a rare manifesta-
tion, and the second might result in underestimation of 
clinically asymptomatic manifestations. With respect 
to malignancies, investigators were not asked to pro-
vide histology findings and no central review of histol-
ogy could be performed. The study was not designed to 
monitor malignancy treatments and their outcomes; 
hence we cannot provide further details. The required 
frequency of radiological tests to monitor cerebral and 
renal manifestations in TSC patients might introduce 
a lead time bias that may affect the conclusions of the 
study with respect to age at diagnosis. Also, the chance 
of long-term genetic damage caused by the radiological 
dose at relatively young ages might be a factor to con-
sider. Although potentially affected by selection bias, it is 
of note that no study participant died from cancer during 
the study. Moreover, the TOSCA registry was not spe-
cifically designed for rare manifestations, hence the inci-
dence of rare manifestations may be underreported.
Conclusion
Rare manifestations occur in a relevant percentage of 
TSC patients. However, variability is high and further 
systematic evaluations are required to shape diagnostic 
and surveillance strategies. Malignancies affected about 
2% of the participants in our study. Compared to the 
overall population, malignant tumors occurred earlier in 
age and were more common in females and participants 
with TSC1 mutation.
Table 7 Malignancies by organ class and age groups
* Melanoma of skin. $5-year prevalence of malignancies have been presented for qualitative comparison between the general population and our cohort
Organs 5-year prevalence of malignancies in 
general population by age group (per 
100, 000)$, 25
Age (years), n (%)
0–9 10–14 15–19 20–39  > 40  ≤ 2
(n = 1)
 > 2– ≤ 5
(n = 3)
 > 5– ≤ 9
(n = 3)
 > 9– ≤ 14
(n = 8)
 > 14– ≤ 18
(n = 2)




Kidney 2.1 0.48 0.51 1.7 34.3 1 (100) 3 (100) 2 (66.7) 3 (37.5) 1 (50.0) 10 (41.7) 11 (45.8)
Breast 0.02 1.2 7.7 46.5 450.5 0 0 0 0 0 1 (4.2) 6 (25)
Thyroid 0.28 4.3 9.5 20.6 54.4 0 0 0 1 (12.5) 1 (50.0) 1 (4.2) 3 (12.5)
Testis 0.97 3.1 6.7 12.0 9.2 0 0 0 0 0 4 (16.7) 1 (4.2)
Ovary 0.62 2.1 3.9 9.5 45.7 0 0 0 1 (12.5) 0 2 (8.3) 1 (4.2)
Brain 3.2 3.4 3.6 5.2 20.7 0 0 0 1 (12.5) 0 0 0
Colon 0.06 0.82 1.7 4.7 170.1 0 0 0 0 0 0 2 (8.3)
Bone, soft tissue – – – – – 0 0 1 (33.3) 0 0 0 1 (4.2)
Pancreas 0.01 0.10 0.26 0.47 9.9 0 0 0 2 (25.0) 0 0 0
Lung 0.06 0.34 0.77 1.8 75.9 0 0 0 0 0 1 (4.2) 1 (4.2)
Skin* 0.11 0.70 1.7 4.2 31.4 0 0 0 0 0 1 (4.2) 0
Eye – – – – – 0 0 0 0 0 1 (4.2) 0
Liver 0.72 0.49 0.84 1.8 22.4 0 0 0 0 0 1 (4.2) 0
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